Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes (Q37799831)

23 August 2017

title

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes (English)

1 reference

chromosomal deletion syndrome

23 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20942636

1 August 2024

Carla Heise

1 reference

23 August 2017

Troy Carter

series ordinal

1 reference

23 August 2017

Peter Schafer

series ordinal

1 reference

23 August 2017

Rajesh Chopra

series ordinal

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20942636

1 August 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

http://www.future-drugs.com/doi/abs/10.1586/era.10.135

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20942636

http://www.tandfonline.com/doi/pdf/10.1586/era.10.135

1 August 2024

1 reference

Expert Review of Anticancer Therapy

1 August 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

1663-1672

1 reference

Proposals for the classification of the myelodysplastic syndromes

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Cancer biology. A matter of dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Inherited susceptibility to common cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Clinical relevance of cytogenetics in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

SPARC and tumor growth: where the seed meets the soil?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Questions about gemcitabine dose rate: answered or unanswered?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Mechanism and function of formins in the control of actin assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

The many faces of actin: matching assembly factors with cellular structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

T cell responses in mammalian diaphanous-related formin mDia1 knock-out mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.135

Myelodysplastic syndromes: incidence and survival in the United States

21 January 2018

1 reference

Myelodysplastic syndromes: an historical perspective.

1 August 2024

1 reference

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome

1 August 2024

1 reference

Journal of Clinical Investigation

1 August 2024

118

2427

Ramsay

2008

1 reference

Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis

1 August 2024

1 reference

1 August 2024

Identifiers

DOI

10.1586/ERA.10.135

1 reference

23 August 2017

1 reference